EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Are we prepared to deliver gene‐targeted therapies for rare diseases?

Timothy W Yu, Stephen F Kingsmore iD, Robert C Green iD, Tippi MacKenzie, Melissa Wasserstein, Michele Caggana, Nina B Gold, Annie Kennedy, Priya S Kishnani, Matthew Might, Phillip J Brooks, Jill A Morris iD und 2 weitere

American Journal of Medical Genetics Part C: Seminars in Medical Genetics · 2023-03 · 193 (1) · 7-12

DOI: 10.1002/ajmg.c.32029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Medical Genetics Part C: Seminars in Medical Genetics, online erschienen am 24.01.2023. Verfasst von Timothy W Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetics and Genomics, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Rare Diseases, Genetic Therapy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cost and time needed to conduct whole‐genome sequencing (WGS) have decreased significantly in the last 20 years. At the same time, the number of conditions with a known molecular basis has steadily increased, as has the number of investigational new drug applications for novel gene‐based therapeutics. The prospect of precision gene‐targeted therapy for all seems in reach… or is it? Here we consider practical and strategic considerations that need to be addressed to establish a foundation for the early, effective, and equitable delivery of these treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rare DiseasesGenetic TherapyHumans

Autor:innen und Institutionen

  • Division of Genetics and Genomics, Harvard Medical School, Boston, Massachusetts, USA.
  • Rady Children's Institute for Genomic Medicine, San Diego, California, USA.
  • Department of Genetics-Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Department of Surgery and the Center for Maternal-Fetal Precision Medicine, University of California, San Francisco, San Francisco, California, USA.
  • Division of Pediatric Genetic Medicine, Children's Hospital at Montefiore, New York, New York, USA.
  • Division of Genetics, New York State Department of Health, Albany, New York, USA.

ORCID-Profile: Stephen F Kingsmore, Robert C Green, Jill A Morris, Melissa A Parisi, Tiina K Urv

Förderung

  • National Center for Advancing Translational Sciences

Zitieren

APA

Yu, T. W., Kingsmore, S. F., Green, R. C., MacKenzie, T., Wasserstein, M., Caggana, M., Gold, N. B., Kennedy, A., Kishnani, P. S., Might, M., Brooks, P. J., Morris, J. A., Parisi, M. A., & Urv, T. K. (2023). Are we prepared to deliver gene‐targeted therapies for rare diseases?. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 193(1), 7-12. https://doi.org/10.1002/ajmg.c.32029

Vancouver

Yu TW, Kingsmore SF, Green RC, MacKenzie T, Wasserstein M, Caggana M, et al. Are we prepared to deliver gene‐targeted therapies for rare diseases?. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2023;193(1):7-12. doi:10.1002/ajmg.c.32029

BibTeX
@article{Yu2023,
  author = {Yu, Timothy W and Kingsmore, Stephen F and Green, Robert C and MacKenzie, Tippi and Wasserstein, Melissa and Caggana, Michele and Gold, Nina B and Kennedy, Annie and Kishnani, Priya S and Might, Matthew and Brooks, Phillip J and Morris, Jill A and Parisi, Melissa A and Urv, Tiina K},
  title = {Are we prepared to deliver gene‐targeted therapies for rare diseases?},
  journal = {American Journal of Medical Genetics Part C: Seminars in Medical Genetics},
  year = {2023},
  volume = {193},
  number = {1},
  pages = {7--12},
  doi = {10.1002/ajmg.c.32029}
}
Kostenlos starten →